Stay updated on Safety and Efficacy of Sparsentan in IgA Nephropathy Clinical Trial
Sign up to get notified when there's something new on the Safety and Efficacy of Sparsentan in IgA Nephropathy Clinical Trial page.

Latest updates to the Safety and Efficacy of Sparsentan in IgA Nephropathy Clinical Trial page
- Check3 days agoChange DetectedThe page’s footer updates the ClinicalTrials.gov build/release revision from **v3.5.2** to **v3.5.3**, indicating a web/version update. No study-specific content or record-history details are altered.SummaryDifference0.1%

- Check10 days agoChange DetectedAdded Revision: v3.5.2 to the history. Removed Revision: v3.5.0.SummaryDifference0.1%

- Check17 days agoNo Change Detected
- Check39 days agoChange DetectedRevision v3.5.0 was added and revision v3.4.3 was removed from the Record History.SummaryDifference0.1%

- Check46 days agoChange DetectedRecord History now shows Revision: v3.4.3 and removes Revision: v3.4.2.SummaryDifference0.1%

- Check74 days agoChange DetectedMinor changes include the addition of Revision: v3.4.2 and the removal of a funding notice, which do not affect the study data, status, or history. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.9%

- Check82 days agoChange DetectedAdded a site-wide notice about government funding status and updated the revision history to v3.4.1, removing the previous v3.4.0 entry.SummaryDifference0.9%

Stay in the know with updates to Safety and Efficacy of Sparsentan in IgA Nephropathy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety and Efficacy of Sparsentan in IgA Nephropathy Clinical Trial page.